Clinical trial registry record

Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 4 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated April 19, 2018.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT02944227
Last registry update
April 19, 2018
Status
Completed
Phase
Phase 4
Sponsor
Seoul National University Hospital
Enrollment
20
Countries
South Korea
Match confidence
80%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 4
Study design
NA · SINGLE GROUP · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
20
Population
ALL
Duration
2016-03-03 to 2017-08-21
Intervention
Lucentis
Comparator
Not reported
Outcomes measured
Changes of a pigment epithelial detachment (PED) — Baseline and 6 months; Changes of subretinal fluid (SRF) — Baseline and 6 months; Change in best corrected visual acuity from baseline — Baseline and 6 months; Changes in subfoveal thickness (SFT) measured by optical coherence tomography (OCT) from baseline — Baseline and 6 mont…; The proportion of cases maintaining vision and also who gained ≥ 15 letters from baseline — Baseline and 6 months; The proportion of cases having complete resolution of SRF associated with serous pigment epithelial detachment (PED) —…; The proportion of cases having complete resolution of subretinal fluid (SRF) associated with fibrovascular pigment epit…; The proportion of cases having persistent or recurrent subretinal fluid (SRF) associated with serous pigment epithelial…; The proportion of cases having persistent or recurrent subretinal fluid (SRF) associated with fibrovascular pigment epi…; The incidence of ocular adverse events — Through study completion, an average of 1 year; The proportion of cases experiencing leakage from neovascular AMD lesions — Baseline and 6 months
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 4A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 80% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 80%Title contains controlled topic terminology. Title supplies ageing or longevity context.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON